EUVIMEDEUVIMED entdecken
Open Access

High Frequency of Artemisinin Partial Resistance Mutations in the Great Lakes Region Revealed Through Rapid Pooled Deep Sequencing

Neeva Wernsman Young iD, Pierre Gashema iD, David Giesbrecht iD, Tharcisse Munyaneza, Felicien Maisha, Fred Mwebembezi, Rule Budodo iD, Alec Leonetti, Rebecca Crudale iD, Vincent Iradukunda, Ntwari Jean Bosco, Rebecca I Kirby iD und 13 weitere

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiae475 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Neeva Wernsman Young und 24 weiteren Autor:innen. Beteiligte Einrichtung: Pathology and Laboratory Medicine, Brown University, Providence, Rhode Island. Hauptthemen laut MEDLINE: Plasmodium falciparum, Antimalarials, Drug Resistance, Artemisinins. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In Africa, the first Plasmodium falciparum artemisinin partial resistance mutation was Kelch13 (K13) 561H, detected and validated at appreciable frequency in Rwanda in 2014. Surveillance to better define the extent of the emergence in Rwanda and neighboring countries is critical.

Methods

We used novel liquid blood drop preservation with pooled sequencing to provide cost-effective rapid assessment of resistance mutation frequencies at multiple collection sites across Rwanda and neighboring regions in Uganda, Tanzania, and the Democratic Republic of the Congo. Malaria-positive samples (N = 5465) from 39 health facilities collected between May 2022 and March 2023 were sequenced in 199 pools.

Results

In Rwanda, K13 561H and 675V were detected in 90% and 65% of sites, with an average frequency of 19.0% (range, 0%–54.5%) and 5.0% (0%–35.5%), respectively. In Tanzania, 561H had high frequency in multiple sites. 561H appeared at 1.6% in Uganda. 561H was absent from the Democratic Republic of the Congo, although 675V was seen at low frequency. Concerningly, candidate mutations were observed: 441L, 449A, and 469F co-occurred with validated mutations, suggesting that they are arising under the same pressures. Other markers for decreased susceptibility to artemether-lumefantrine are common: P falciparum multidrug resistance protein 1 N86 at 98.0% (range, 63.3%–100%) and 184F at 47.0% (0%–94.3%) and P falciparum chloroquine resistance transporter 76T at 14.7% (0%–58.6%). Additionally, sulfadoxine-pyrimethamine–associated mutations show high frequencies.

Conclusions

K13 mutations are rapidly expanding in the region, further endangering control efforts with the potential of engendering partner drug resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plasmodium falciparumAntimalarialsDrug ResistanceArtemisininsMutationMalaria, FalciparumHumansHigh-Throughput Nucleotide SequencingUgandaDemocratic Republic of the CongoTanzaniaProtozoan ProteinsRwanda

Stichwörter der Autor:innen

East Africaartemisinindrug resistancekelch13malaria

Substanzen

AntimalarialsArtemisininsartemisininProtozoan Proteins

Autor:innen und Institutionen

  • Pathology and Laboratory Medicine, Brown University, Providence, Rhode Island.
  • Center for Computational and Molecular Biology, Brown University, Providence, Rhode Island.
  • Center for Genomic Biology, Institut d'Enseignement Supérieur de Ruhengeri, Ruhengeri, Rwanda.
  • National Reference Laboratory, Rwanda Biomedical Center, Kigali.
  • Department of Pediatrics, HEAL Africa Hospital, Goma, Democratic Republic of the Congo.
  • Department of Community Health, Mbarara University of Science and Technology, Uganda.

ORCID-Profile: Neeva Wernsman Young, Pierre Gashema, David Giesbrecht, Rule Budodo, Rebecca Crudale, Rebecca I Kirby, Ross M Boyce, Grace K Kanyankole, Oliver J Watson, Deus S Ishengoma, Corine Karema, Jonathan J Juliano

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Wernsman Young, N., Gashema, P., Giesbrecht, D., Munyaneza, T., Maisha, F., Mwebembezi, F., Budodo, R., Leonetti, A., Crudale, R., Iradukunda, V., Jean Bosco, N., Kirby, R. I., Boyce, R. M., Mandara, C. I., Kanyankole, G. K., Ntaro, M., Okell, L. C., Watson, O. J., Mulogo, E., …, & Bailey, J. A. (2025). High Frequency of Artemisinin Partial Resistance Mutations in the Great Lakes Region Revealed Through Rapid Pooled Deep Sequencing. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae475

Vancouver

Wernsman Young N, Gashema P, Giesbrecht D, Munyaneza T, Maisha F, Mwebembezi F, et al. High Frequency of Artemisinin Partial Resistance Mutations in the Great Lakes Region Revealed Through Rapid Pooled Deep Sequencing. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiae475

BibTeX
@article{WernsmanYoung2025,
  author = {Wernsman Young, Neeva and Gashema, Pierre and Giesbrecht, David and Munyaneza, Tharcisse and Maisha, Felicien and Mwebembezi, Fred and Budodo, Rule and Leonetti, Alec and Crudale, Rebecca and Iradukunda, Vincent and Jean Bosco, Ntwari and Kirby, Rebecca I and Boyce, Ross M and Mandara, Celine I and Kanyankole, Grace K and Ntaro, Moses and Okell, Lucy C and Watson, Oliver J and Mulogo, Edgar and Ishengoma, Deus S and Hangi, Stan and Karema, Corine and Mazarati, Jean-Baptiste and Juliano, Jonathan J and Bailey, Jeffrey A},
  title = {High Frequency of Artemisinin Partial Resistance Mutations in the Great Lakes Region Revealed Through Rapid Pooled Deep Sequencing},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiae475}
}
Kostenlos starten →